You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
萊美藥業(300006.SZ):取得阿奇黴素顆粒的藥品註冊證書
格隆匯 06-24 16:02

格隆匯6月24日丨萊美藥業(300006.SZ)公佈,近日,重慶萊美藥業股份有限公司收到國家藥品監督管理局核准簽發的阿奇黴素顆粒(規格:0.1g按C₃₈H₇₂N₂O₁₂計)《藥品註冊證書》。

阿奇黴素是一種大環內酯類抗生素,阿奇黴素顆粒臨牀上適用於敏感細菌所引起的感染,包括支氣管炎、肺炎等下呼吸道感染;皮膚和軟組織感染;急性中耳炎;鼻竇炎、咽炎、扁桃體炎等上呼吸道感染;沙眼衣原體所導致的單純性生殖器感染等。

截止目前,除公司外共有41家企業取得阿奇黴素顆粒藥品註冊證書。根據藥融雲數據顯示:阿奇黴素顆粒2022-2024年上半年在中國醫院(全終端)市場銷售額分別為1.20億元、1.27億元、0.95億元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account